A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic event is translocation of musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a transcriptional activator of key targe...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Annunziata, Christina M., Hernandez, Lidia, Davis, R. Eric, Zingone, Adriana, Lamy, Laurence, Lam, Lloyd T., Hurt, Elaine M., Shaffer, Arthur L., Kuehl, W. Michael, Staudt, Louis M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2011
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062408/
https://ncbi.nlm.nih.gov/pubmed/21163924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-278788
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky